Tanning & Libido

PT-141

Bremelanotide (PT-141)

The only FDA-approved peptide specifically for sexual dysfunction

PT-141 (Bremelanotide) is a melanocortin receptor agonist that works in the brain to increase sexual desire. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in women.

PT-141 illustration

Admin routes

Subcutaneous

Popularity

Medium

Side effects

Generally mild

Vendors

5 rated

Key benefits

1Increases sexual desire and arousal in both sexes
2Works centrally (brain) - increases desire, not just mechanics
3FDA-approved for HSDD in women (Vyleesi)
4Effective in men who don't respond to PDE5 inhibitors
5Effects last 12–24 hours per dose
6Does not require arousal to work (unlike PDE5 inhibitors)

What to expect

1
Single dose

Effects within 30–60 minutes; lasts 6–12 hours

2
First few uses

Optimal dose found through titration (start low)

3
Ongoing

Used as-needed; no daily protocol required

Based on community reports and published research. Individual results vary significantly.

🏪Rated vendors

View all →

Vendor ratings are based on community feedback and are not endorsements. Always verify third-party certificates of analysis (CoA) and check your local regulations before purchasing.

Dosing protocols

Sexual dysfunction

Dose

1.75 mg (FDA-approved dose)

Frequency

As needed, 45 min before activity

Duration

As needed (max once per 24 hours)

Research / lower dose

Dose

500–1000 mcg

Frequency

As needed

Duration

As needed

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|FDA-approved (Vyleesi) - Phase 3 clinical data

Overview

PT-141 (Bremelanotide, brand name Vyleesi) was originally derived from Melanotan 2 research when scientists noticed MT-2's pronounced libido-enhancing effects. PT-141 was specifically optimised for sexual function, targeting MC4R receptors in the brain that regulate sexual arousal and desire. Unlike PDE5 inhibitors (Viagra, Cialis) which work on blood flow mechanics, PT-141 acts centrally - it increases desire and arousal rather than just enabling physical response. It was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first peptide approved specifically for sexual dysfunction.

How it works

PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system - brain areas involved in sexual desire and arousal. This is fundamentally different from PDE5 inhibitors which work peripherally on blood vessel smooth muscle. By acting centrally, PT-141 increases desire (wanting) rather than just physical capability. It also has some MC1R activity (causing mild tanning) and MC3R activity (appetite effects), though these are less pronounced than with MT-2 due to its optimised receptor selectivity.

Side effects

Nausea (most common, ~40% of users)
moderateCommon
Flushing
mildCommon
Headache
mildCommon
Injection site reactions
mildCommon
Temporary increase in blood pressure
moderateUncommon
Skin darkening with repeated use (MC1R activity)
mildUncommon

Research history

2000

Derived from Melanotan 2 research at University of Arizona

2007

Phase 3 clinical trials for female sexual dysfunction begin

2019

FDA approves bremelanotide (Vyleesi) for HSDD in women

2020s

Off-label use expands to male sexual dysfunction

2024

Research into additional MC receptor-mediated applications

PT-141 vs Viagra/Cialis

The key difference is mechanism. Viagra and Cialis (PDE5 inhibitors) increase blood flow to erectile tissue - they enable the physical response but don't affect desire. PT-141 works in the brain to increase desire and arousal. This makes PT-141 effective in cases where PDE5 inhibitors fail, particularly when the issue is low desire rather than physical dysfunction. Some practitioners use PT-141 in combination with PDE5 inhibitors for patients with both low desire and erectile dysfunction.

Recommended products

Hand-picked for this compound. Ships via Amazon 🇺🇸

Affiliate links — small commission at no extra cost to you.All essentials →

References

  1. [1]Clayton AH, et al. "Bremelanotide for hypoactive sexual desire disorder in premenopausal women (RECONNECT)." Obstetrics & Gynecology, 2019.
  2. [2]Diamond LE, et al. "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)." Journal of Sexual Medicine, 2006.

Frequently asked questions

Related peptides

Community experiences

Share your experience with PT-141. Effects, side effects, protocol details - help others make informed decisions.

Write a review

Rating:

No community reviews yet. Be the first to share your experience with PT-141.

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for PT-141.

Open Calculator

Found this useful?

Share this guide

Get the free Beginner Peptide Protocol

Which peptides to start with, what to avoid, and safe handling. Delivered to your inbox.

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Check your local regulations regarding peptide purchase and use.